Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling

BACKGROUND: One of the major challenges in managing invasive breast cancer (BC) is the lack of reliable biomarkers to track response. Circulating tumor DNA (ctDNA) from liquid biopsy, as a candidate biomarker, provides a valuable assessment of BC patients. In this retrospective study, we evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhanhong, Sun, Tian, Yang, Ziyan, Zheng, Yabing, Yu, Ruoying, Wu, Xue, Yan, Junrong, Shao, Yang W, Shao, Xiying, Cao, Wenming, Wang, Xiaojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005625/
https://www.ncbi.nlm.nih.gov/pubmed/31867841
http://dx.doi.org/10.1002/mgg3.1079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005625/
https://www.ncbi.nlm.nih.gov/pubmed/31867841
http://dx.doi.org/10.1002/mgg3.1079

Ejemplares similares